The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rafael Venegas Rodríguez, Anabel Serrano Díaz, Rubén Peña Ruiz, Raúl Santana Sánchez, Aliusha Rittoles Navarro, Inti Grecesqui Cruz, Liam Manuel Pérez Aguilera, Anadys Segura Fernández, Mabel Hernández-Cedeño, Leticia Rosario Cruz, Deyli Chacón Montano, Gillian Martínez-Donato, Gerardo Guillén-Nieto, María del Carmen Domínguez Horta
Formato:	article
Lenguaje:	ES
Publicado:	ECIMED 2021
Materias:	covid-19 hiperinflamación hipercoagulación hsp60 cigb-258 jusvinza. Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1bbf749ca5744f84841c0b91c9011f33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1bbf749ca5744f84841c0b91c9011f33
record_format	dspace
spelling	oai:doaj.org-article:1bbf749ca5744f84841c0b91c9011f332021-11-30T13:31:08ZThe treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-191561-3046https://doaj.org/article/1bbf749ca5744f84841c0b91c9011f332021-11-01T00:00:00Zhttp://www.revmedmilitar.sld.cu/index.php/mil/article/view/1675https://doaj.org/toc/1561-3046Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptoms of hyperinflammation. Objectives: To describe the clinical course and behavior of various biomarkers associated with the inflammation and coagulation, in a group of critically ill patients with COVID-19 treated with Jusvinza, compared to a group of patients who did not receive treatment with this peptide. Methods: 40 critically ill patients with COVID-19 were included. The patients were divided into 2 groups: 20 patients were treated with Jusvinza and 20 were not treated with this peptide (control group). Demographic characteristics, comorbidities, vital signs, respiratory parameters and inflammation and coagulation biomarkers were obtained from the medical records of each patient. Results: Treatment with Jusvinza induced a clinical improvement in the patients, associated with the decrease of several inflammation and coagulation biomarkers. Patients treated with Jusvinza had a significantly higher survival than patients not treated with this peptide. Conclusions: Jusvinza is able to control hyperinflammation and hypercoagulation in critical ill patients with COVID-19.Rafael Venegas RodríguezAnabel Serrano DíazRubén Peña RuizRaúl Santana SánchezAliusha Rittoles NavarroInti Grecesqui CruzLiam Manuel Pérez AguileraAnadys Segura FernándezMabel Hernández-CedeñoLeticia Rosario CruzDeyli Chacón MontanoGillian Martínez-DonatoGerardo Guillén-NietoMaría del Carmen Domínguez HortaECIMEDarticlecovid-19hiperinflamaciónhipercoagulación hsp60cigb-258jusvinza.MedicineRMedicine (General)R5-920ESRevista Cubana de Medicina Militar, Vol 50, Iss 4, Pp e02101675-e02101675 (2021)
institution	DOAJ
collection	DOAJ
language	ES
topic	covid-19 hiperinflamación hipercoagulación hsp60 cigb-258 jusvinza. Medicine R Medicine (General) R5-920
spellingShingle	covid-19 hiperinflamación hipercoagulación hsp60 cigb-258 jusvinza. Medicine R Medicine (General) R5-920 Rafael Venegas Rodríguez Anabel Serrano Díaz Rubén Peña Ruiz Raúl Santana Sánchez Aliusha Rittoles Navarro Inti Grecesqui Cruz Liam Manuel Pérez Aguilera Anadys Segura Fernández Mabel Hernández-Cedeño Leticia Rosario Cruz Deyli Chacón Montano Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
description	Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptoms of hyperinflammation. Objectives: To describe the clinical course and behavior of various biomarkers associated with the inflammation and coagulation, in a group of critically ill patients with COVID-19 treated with Jusvinza, compared to a group of patients who did not receive treatment with this peptide. Methods: 40 critically ill patients with COVID-19 were included. The patients were divided into 2 groups: 20 patients were treated with Jusvinza and 20 were not treated with this peptide (control group). Demographic characteristics, comorbidities, vital signs, respiratory parameters and inflammation and coagulation biomarkers were obtained from the medical records of each patient. Results: Treatment with Jusvinza induced a clinical improvement in the patients, associated with the decrease of several inflammation and coagulation biomarkers. Patients treated with Jusvinza had a significantly higher survival than patients not treated with this peptide. Conclusions: Jusvinza is able to control hyperinflammation and hypercoagulation in critical ill patients with COVID-19.
format	article
author	Rafael Venegas Rodríguez Anabel Serrano Díaz Rubén Peña Ruiz Raúl Santana Sánchez Aliusha Rittoles Navarro Inti Grecesqui Cruz Liam Manuel Pérez Aguilera Anadys Segura Fernández Mabel Hernández-Cedeño Leticia Rosario Cruz Deyli Chacón Montano Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta
author_facet	Rafael Venegas Rodríguez Anabel Serrano Díaz Rubén Peña Ruiz Raúl Santana Sánchez Aliusha Rittoles Navarro Inti Grecesqui Cruz Liam Manuel Pérez Aguilera Anadys Segura Fernández Mabel Hernández-Cedeño Leticia Rosario Cruz Deyli Chacón Montano Gillian Martínez-Donato Gerardo Guillén-Nieto María del Carmen Domínguez Horta
author_sort	Rafael Venegas Rodríguez
title	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
title_short	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
title_full	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
title_fullStr	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
title_full_unstemmed	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
title_sort	treatment with jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with covid-19
publisher	ECIMED
publishDate	2021
url	https://doaj.org/article/1bbf749ca5744f84841c0b91c9011f33
work_keys_str_mv	AT rafaelvenegasrodriguez thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT anabelserranodiaz thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT rubenpenaruiz thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT raulsantanasanchez thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT aliusharittolesnavarro thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT intigrecesquicruz thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT liammanuelperezaguilera thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT anadyssegurafernandez thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT mabelhernandezcedeno thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT leticiarosariocruz thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT deylichaconmontano thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT gillianmartinezdonato thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT gerardoguillennieto thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT mariadelcarmendominguezhorta thetreatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT rafaelvenegasrodriguez treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT anabelserranodiaz treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT rubenpenaruiz treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT raulsantanasanchez treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT aliusharittolesnavarro treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT intigrecesquicruz treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT liammanuelperezaguilera treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT anadyssegurafernandez treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT mabelhernandezcedeno treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT leticiarosariocruz treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT deylichaconmontano treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT gillianmartinezdonato treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT gerardoguillennieto treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19 AT mariadelcarmendominguezhorta treatmentwithjusvinzareduceshyperinflammationandhypercoagulationincriticalillpatientswithcovid19
_version_	1718406549374763008

The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

Ejemplares similares